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Tracking malaria transmission at the antenatal clinic
The development of resistance to sulfadoxine-
pyri methamine is a t hreat to the eﬀ ectiveness of 
intermittent preventive treatment for malaria during 
pregnancy (IPTp), especially in areas of east Africa where 
the A581G molecular marker denoting super-resistance 
is prevalent.1,2 As a result, alternative strategies for 
protection from malaria during pregnancy are being 
explored.3 One idea, intermittent screening and 
treatment during pregnancy (ISTp), involves a rapid 
diagnostic test (RDT) for the screening of women who 
present to antenatal clinics and use of highly eﬀ ective 
artemisinin-based drugs to treat those with malaria 
parisitaemia.
As Anna Maria van Eijk and colleagues4 highlight in 
The Lancet Global Health, the inclusion of rapid diagnostic 
tests for malaria in to routine care at antenatal clinics 
could provide a valuable and extremely convenient 
source of information about local patterns in malaria 
transmission. Further, such a strategy has become 
feasible since the price of RDT has decreased sharply. 
However, for these data to be useful as a surveillance tool 
we must understand the relation between prevalence in 
pregnant women and the endemicity of infection in the 
general population, especially in children who are the 
most commonly sampled sentinels of infection and who 
bear most of the malaria burden.
This relationship will be complicated: the prevalence 
of malaria infection in non-pregnant adults is lower 
than that for children within the same setting,5 a ﬁ nding 
probably related to the diﬀ ering levels of immunity 
in the adult and child populations. Since immunity 
depends on previous exposure and also the longevity 
of infection,6,7 it will, then, vary with transmission 
intensity.5 
Pregnancy provides a second layer of complexity: 
around the time that maternal blood ﬂ ows into the 
placenta, the Plasmodium falciparum parasite (the 
most prevalent and pathogenic species of plasmodia) 
is able to sequester within the intervillous space.8 In 
women who have not been exposed to malaria during 
a previous pregnancy, the parasite  can replicate to very 
high densities. Although women in their second or 
subsequent pregnancies will probably be exposed to a 
similar risk of infection as that in their ﬁ rst pregnancy,9 
acquired immunity to placental parasites will allow 
multigravidae to more eﬀ ectively control parasite 
replication within the placenta than was possible in their 
ﬁ rst pregnancy.8 Because parasite biomass is likely to 
be heavily linked to the level of antigen the diagnostic 
is designed to detect (usually histidine-rich protein 2 
(HRP-2),10 it seems reasonable to expect that malaria 
prevalence in later pregnancies will also follow a distinct 
pattern dependent on transmission intensity.
The strong correlation between infection in pregnant 
women and children established by van Eijk and 
colleagues,4 using extensive large-scale cross-sectional 
prevalence data in the two groups, is grounds for 
optimism about the usefulness of these data as an 
indicator of transmission. Moreover, results of van Eijk 
and colleagues’ analysis provides insight into the next 
steps to follow in the search of a metric that can be 
readily used. Their results suggest that, in areas of low 
transmission, prevalence in pregnant women is likely 
to be very similar to that in young children, but that, as 
transmission reaches higher intensities, cross-sectional 
prevalence surveys of pregnant women will increasingly 
underestimate those in children. 
Although based on fewer data, malaria prevalence 
in primigravidae seems to be a much more reliable 
indicator in highly endemic settings, consistently 
representing approximately 86% of that in children, 
including settings where up to 80% of children have 
parasitaemia detectable by microscopy. This ﬁ nding 
suggests another important potential intersection 
between achieving adequate care for malaria during 
pregnancy and monitoring transmission: primigravidae 
provide the most accurate information about the nature 
of transmission and are also most likely to have negative 
health outcomes as a result of infection, so, therefore, 
are most likely to beneﬁ t from a strategy that leads 
to improved care when infection during pregnancy is 
detected.
Understanding how advances in malaria diagnostics 
can be best used to beneﬁ t pregnant women is, 
however, not straightforward. RDTs are not perfectly 
sensitive in the detection of infection during pregnancy.9 
Further, antimalarial drugs, including sulfadoxine-
pyrimethamine, provide a period of prophylaxis against 
infection—meaning that, under the IPTp protocol, even 
women who do not have malaria parisitaemia detected 
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at an antenatal clinic would receive presumptive 
treatment and beneﬁ t from decreased levels of exposure 
to malaria as a result. 
Understanding how (or whether) the diagnosis of 
malaria infec tion in pregnancy can be of direct beneﬁ t 
to pregnant women, either in terms of safety, eﬃ  cacy, 
eﬀ ective ness, or acceptability, of an intervention will 
be crucial in determining whether pregnant women 
at antenatal clinics are a viable resource for malaria 
surveillance.
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